The company will use the funds to continue development of a drug for the treatment of Alzheimer’s disease (AD). This financing supports the progression of its compounds with the initial objective of delivering an AD drug candidate into first-in-man clinical testing. The final goal is to provide a drug that prevents the progression of disease.
Led by William McIntosh, Chairman and CEO, Treventis has leveraged a proprietary drug design platform to synthesize a class of organic drug-like molecules with the capability of binding to both beta-amyloid and tau, preventing aggregation of both proteins using a single drug.
The principal investigator is board-certified neurologist and renowned medicinal chemist Donald F. Weaver, MD, PhD.
The company has research operations in Toronto, Ontario, and Halifax, Nova Scotia, Canada.